PubMed Health⌕ Search

Biomedical subjects

N Cellini

Publications and source records attributed to N Cellini.

53 records · Page 3Linked to original sources
PubMedDate not supplied

[Role of computerized tomography in the definition of the area to be irradiated in bone metastases].

In the Department of Radiology of the Catholic University S. Cuore in Rome, a review was made of 342 CT examinations with a view towards optimizing the therapeutic planning in patients affected by bone metastases. All patients were submitted to radiological positioning and then to CT evaluation in order to assess the volume to be treated. In 224 cases it was not necessary to perform wide CT examination (3-5 standard tomograms being enough, 2 of which at the superior and inferior margins of the planned field). In the second group of 118 patients it was necessary to perform CT (serial axial scans)--increasing by 1-1.5 cm--up to the superior and inferior margins of the lesion. The existence of 2 types of lesions was confirmed: those involving mainly bony structures and those infiltrating the soft tissues. CT evaluation allowed the definition of the target volume to the real extension of the lesion in 14% of the whole of cases, while in the group of 118 cases studied more thoroughly, the percentage went up to 41%. CT allowed a better assessment of secondary bone lesions, especially in kidney and lung neoplasms. The metastatic site that required a more frequent modification of the irradiation field was the chest. To conclude, the authors emphasize the importance of CT in assessing the target volume, especially in those cases in which conventional radiology does not allow a reliable evaluation of the lesion, possibly compromising the local monitoring of the disease.

Bone Neoplasms↗
PubMedDate not supplied

Radiotherapy in rectal cancer: stage of the disease and therapeutic approach.

Rectal cancer requires treatments tailored according to the stage of the disease at diagnosis. In stage I lesions exclusive surgery is the elective treatment. Radiotherapy is used in those cases where the site of the lesion would sacrifice sphincter function. When the features of neoplasm are favourable (size < 5 cm, grading 1-2, histological type adenocarcinoma) local excision and postoperative radiotherapy enable to achieve results comparable to those of radical surgery. In operable lesions (T3-T4 (vagina) N0-2, M0) at high risk for local recurrence, high dose preoperative radiotherapy in some randomized studies has shown a significant improvement in local control and survival with a low toxicity, especially in patients undergoing radical surgery. Concomitant chemotherapy in postoperative radiotherapy has significantly improved local control and survival as compared to radiotherapy alone. Continuous infusion appears to reduce the toxicity, which is otherwise high. Randomized studies of preoperative radiochemotherapy vs radiation alone or vs postoperative radiochemotherapy are in progress in various Centers. Intensification with radiotherapy alone (IORT, fractionation) is also under study. In lesions unresectable for cure (T4, N0-3, M0) radiotherapy alone or combined with surgery did not show significant results. Intensification with concomitant chemotherapy and/or with IORT has enabled over 70% local control and 50% 5-year survival.

Adenocarcinoma↗
PubMedDate not supplied

Intraoperative radiation therapy (IORT) in rectal cancer: methodology and indications.

In intraoperative radiation therapy (IORT) a high dose of radiation is delivered to the tumor or to the tumor bed, thus favouring local control with no significant increase in toxicity. At present it is used to deliver a boost dose of radiation for rectal cancer in protocols which include preoperative external beam radiation therapy (ERT). From various experiences carried out in a number of centers, the technical and methodological features of this procedure have been defined also relatively to cost-effectiveness in terms of a longer surgical treatment, involved specialized staff and resources. At the 5th IORT International Congress held in Lyon in September, 1994, of over 70 clinical studies reported, 15 were on rectal cancer with about 700 patients undergoing IORT. The growing interest in the use of this procedure in rectal cancer is explained by the natural history of the disease, burdened with a high rate of local recurrence, and by the possibility of preventing it with high doses of radiation. In primary tumors unresectable for cure and in local recurrence it is evidenced that ERT+surgery+IORT enable an improvement in local control and survival as compared to ERT alone. Results are better when surgery is radical. Several studies deal with the role of preoperative combined concomitant radiochemotherapy which can favour a radical surgery. A sizeable percentage of these patients will present with metastasis, thus adjuvant chemotherapy seems suitable. A role of IORT is envisaged also for resectable high risk tumors, however results should be confirmed by larger clinical series.

Combined Modality Therapy↗
PubMedDate not supplied

Concomitant radiochemotherapy in rectal cancer: methodology and indications.

Concomitant radiochemotherapy (CRC) is based on the administration of chemotherapeutic agents concurrently with radiation therapy. It is aimed at the spatial cooperation of radiotherapy (ERT) and chemotherapy and the enhancement of the local action of radiotherapy. In this study the role of ERT enhancement in the treatment of rectal cancer, is analyzed. 5FU is the commonly used drug. Clinical and experimental evidence indicates radiotherapy to be enhanced when the drug is administered in continuous infusion after radiation and for a suitable dose of 5FU. In these conditions, toxicity is usually mild. In contrast, when the drug is administered as bolus, the experimental evidence seems to indicate only additivity. However the clinical experience has shown an improvement in local control and survival at the expense of a higher toxicity. In patients with resectable lesions at high risk for local recurrence, randomized CRC studies have shown a high rate of local control between 85% and 90%, a 5-year survival between 55% and 60%, significantly better as compared to control arms: exclusive surgery (GITSG7 175), exclusive ERT (NCCTG), bolus CRC (Intergroup). Acute toxicity is mostly hematological and gastrointestinal. In patients with lesions unresectable for cure, CRC allows high surgical radicality (85-90%). Complete pathologic response is 4 to 20%. Local control is high (80-90%) and 3-year survival is 70 to 90%. Grade 3-4 acute gastrointestinal toxicity was shown to be higher in combinations with bolus 5FU. In recurrence CRC has been used for palliation. Control of pain to the pelvis was similar to that achieved with radiotherapy alone. In a single experience was CRC used preoperatively and results seem encouraging.

Combined Modality Therapy↗